Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Clinical trial NCT02883556 · COMPLETED
Trial details
- NCT number
- NCT02883556
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-27
- Primary completion
- 2019-03-23
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.